Serological and clinical aspects of autoimmune hemolytic anemias

Infusionstherapie und Transfusionsmedizin

Volumn 29, Issue 4, 2002, Pages 206-217

  Salama, Abdulgabar ^a   Ahrens, N ^a   Kiesewetter, H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Anemia; Autoimmune hemolytic anemia; Hemolytic anemia; Immune hemolysis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; COLD AGGLUTININ; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DEXAMETHASONE; ERYTHROCYTE ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PREDNISOLONE; PREDNISONE; RITUXIMAB;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TRANSFUSION; CLINICAL FEATURE; COLD EXPOSURE; COMPLEMENT ACTIVATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; ERYTHROCYTE; HEMODIALYSIS; HEMOLYSIS; HUMAN; LYMPHOPROLIFERATIVE DISEASE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHAGOCYTOSIS; PLASMAPHERESIS; REVIEW; SEROLOGY; SPLENECTOMY; SURVIVAL; TEMPERATURE; VIRUS INFECTION;

EID: 0036060391     PISSN: 14245485     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065316     Document Type: Review

References (157)

1. Nachweis von erythrozytären antigenen und antikörpern
2. The destruction of red cells by antibodies in man. I. Observations on the sequestration and lysis of red cells altered by immune mechanisms
3. The destruction of red cells by antibodies in man. III. Quantitative factors influencing the pattern of hemolysis in vivo
4. Red cells coated with immunoglobulin G: Binding and sphering by mononuclear cells in man
5. The interaction between human monocytes and red cells. Binding characteristics
6. Phagocytosis of erythrocytes sensitized with known amounts of IgG1 and IgG3 anti-Rh antibodies
7. The significance of IgG on the red cell surface
8. Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI)
9. Autoimmune hemolytic anemia associated exclusively with IgA of Rh specificity
10. Acquired immune hemolytic anemia associated with IgA erythrocyte coating: Investigation of hemolytic mechanisms
11. Autoimmune hemolytic anemia associated with IgA - Diagnostic and therapeutic aspects in a case with long-term follow-up
12. Autoimmune hemolytic anemia associated with an IgA autoanti-Gerbich
13. Autoimmune haemolytic anaemia in childhood associated with non-complement binding IgM autoantibodies
14. Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man
15. NIH conference. Pathophysiology of immune hemolytic anemia
16. Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis
17. The interaction of phagocytic cells and red cells modified by immune reactions. Comparison of antibody and complement coated red cells
18. The role of membrane receptors for C3b and C3d in phagocytosis
19. The role of complement in immunohematology
20. The control of homologous lysis
21. Control of the complement system
22. Complement. First of two parts
23. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte
24. Delayed hemolytic transfusion reactions. Evidence for complement activation involving allogeneic and autologous red cells
25. Binding of fluid phase C3b to nonsensitized bystander human red cells. A model for in vivo effects of complement activation on blood cells
26. The interpretation of a positive direct antiglobulin test
27. The autoimmune haemolytic anaemias
28. Autoimmune hemolytic anemia
29. The autoimmune haemolytic anaemias
30. Autoimmune hemolytic anemia. Natural history and viral-immunologic interactions in childhood
31. Autoimmune hemolytic anemia in children. A review of 80 cases
32. Autoimmune haemolytic anaemia in children
33. The acute and transient nature of idiopathic immune hemolytic anemia in childhood
34. Auto-immune haemolytic anaemia in childhood: Follow-up in 29 cases
35. Increased RBC autoantibody production in pregnancy
36. Immunologic mechanisms in autoimmune hemolytic disease
37. Autoimmune hemolytic anemia
38. Clinical aspects of autoimmune hemolytic anemia
39. Serology of acquired hemolytic anemias
40. Serologic profile in autoimmune hemolytic disease: Pathophysiologic and clinical interpretations
41. Red cell autoantibodies, multiple immunoglobulin classes, and autoimmune hemolysis
42. Small quantities of erythrocyte bound immunoglobulins and autoimmune haemolysis
43. Coombs-negative immune hemolytic anemia
44. Hemolytic warm IgM autoagglutinins in autoimmune hemolytic anemia
45. Fatal immune hemolytic anemia and hepatic failure associated with a warm-reacting IgM autoantibody
46. Severe autoimmune hemolytic anemia associated with IgM warm autoantibodies directed against determinants on or associated with glycophorin A
47. Fatal autoimmune hemolytic anemia in a child due to warm-reactive immunoglobulin M antibody
48. Autoimmune hemolytic anemia
49. Drug-induced immune hemolytic anemia
50. Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate
51. Red cell antibodies arising from solid organ transplants
52. Donor-derived alloantibodies and passenger lymphocyte syndrome in two of four patients who received different organs from the same donor
53. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility
54. Drug therapy of autoimmune hemolytic anemia
55. Autoimmune haemolysis: An 18-year study of 865 cases referred to a regional transfusion centre
56. IgG therapy in autoimmune haemolytic anaemia of warm type
57. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin
58. Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type
59. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab)
60. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia
61. The cold hemagglutinin disease
62. Anti-i: A new cold antibody
63. Cold agglutinin anti-I andMycoplasma pneumoniae
64. The definition of two I antigen components
65. Lymphoproliferative disease with IgM lambda monoclonal protein and autoimmune hemolytic anemia. A report of four cases and a review of the literature
66. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins)
67. Cold agglutinins - Antibodies with biological diversity
68. Etiologic aspects of cold agglutinin disease: Evidence for cytogenetically defined clones of lymphoid cells and the demonstration that an anti-Pr cold autoantibody is derived from a chromosomally aberrant B cell clone
69. Cryptic cold agglutinin activity of monoclonal macroglobulins
70. Cold agglutination
71. The variability of hemolysis in the cold agglutinin syndrome
72. Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins
73. Cold haemagglutinin disease: Clinical significance of serum haemolysins
74. Chronic hemolytic anemia due to cold agglutinins. II. The role of C' in red cell destruction
75. Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome
76. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man
77. Increased efficiency of binding of nascent C3b to the erythrocytes of chronic cold agglutinin disease
78. Deposition of the terminal C5b-9 complement complex on erythrocytes by human red cell autoantibodies
79. A cold agglutinin of the IgA class
80. An IgA high-titer cold agglutinin with an unusual blood group specificity within the Pr complex
81. Specificity of IgA cold agglutinins: Anti-Pr 1
82. Hemolytic anemia with IgG and IgM autoantibodies and allontibodies
83. Autoimmune haemolytic anaemia with the unusual combination of both IgM and IgG autoantibodies
84. Cold hemagglutinin disease associated with IgG cold-reactive antibody
85. A new red blood cell cold autoantibody (anti-Me)
86. Autoimmune hemolytic anemia caused by a cold agglutinin with a new specificity (anti-Ju)
87. Cold agglutinin hemolytic anemia: Management with an environmental suit
88. Management of cold agglutination syndrome
89. Rituxan in the treatment of cold agglutinin disease
90. Rituximab: A very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma
91. Studies on the serology of paroxysmal cold haemoglobinuria (PCH) with special reference to its relationship with the P blood group system
92. Paroxysmal cold haemoglobinuria. The most frequent acute autoimmune haemolytic anaemia in children?
93. Donath-Landsteiner autoimmune hemolytic anemia in children. A study of 22 cases
94. The specificity of the antibody in paroxysmal cold hemoglobinuria (PCH)
95. Acute paroxysmal cold hemoglobinuria
96. Paroxysmal cold hemoglobinuria: Report of a case with an exceptionally high thermal range Donath-Landsteiner antibody
97. An unusual Donath-Landsteiner antibody detectable at 37 degrees C by the antiglobulin test
98. Two cases of paroxysmal cold hemoglobinuria with a Donath-Landsteiner antibody reactive by the indirect antiglobulin test using anti-IgG
99. Drug-induced hemolysis
100. Immune drug-induced hemolytic anemias
101. Studies of hypersensitivity to low molecular weight substances. III. The 2,4-dinitrophenyl group as a determinant in the preciptin reaction
102. Allergic reactions in man
103. Drug disposition and drug hypersensitivity
104. The pathogenesis of thromcytopenic purpura due to hypersensitivity to sedormid
105. Drug-induced thrombocytopenia. An immunological phenomenon
106. Drug-induced thrombocytopenia
107. A mechanism of cell destruction in individuals sensitized to foreign antigens and its implications in auto-immunity. Combined clinical staff conference at the National Institutes of Health
108. Coombs-positive hemolytic anemia caused by penicillin administration
109. Immunohemolytic anemia due to antipenicillin antibodies. Report of a case
110. Penicillin-induced haemolytic anaemia
111. Hemolytic anemia caused by penicillin. Report of a case in which antipenicillin antibodies cross-reacted with cephalothin sodium
112. Two mechanisms of erythrocyte destruction in penicillin-induced hemolytic anemia
113. Penicillin-induced immune hemolytic anemia. Occurrence of massive intravascular hemolysis
114. Penicillin-induced immunohemolytic anemia associated with circulating immune complexes
115. Studies on the mechanism of the formation of the penicillin antigen
116. Studies on penicillin hypersensitivity
117. The preparation and some properties of penicillenic acid derivatives relevant to penicillin hypersensitivity
118. Hypersensitivity to penicillenic acid derivatives in human beings with penicillin allergy
119. Minor haptenic determinant-specific reagins of penicillin hypersensitivity in man
120. Functional heterogeneity of antibody to penicilloyl coated erythrocytes
121. Cephaloridine. Studies of therapeutic activity and untoward effects
122. Hemolytic anemia associated with cephalothin
123. Acute intravascular haemolysis associated with cephalexin therapy
124. Hemolysis induced by cefazolin and cephalothin in a patient with penicillin sensitivity
125. Extravascular hemolysis following the administration of cefamandole
126. 'Immune complex' mediated intravascular hemolysis due to IgM cephalosporin-dependent antibody
127. Cefotaxime-induced immune hemolytic anemia due to antibodies reacting in vitro by more than one mechanism
128. Warm autoantibody following plasma apheresis, complicated by acute intravascular hemolysis associated with cefoxitin-dependent antibody resulting in fatality
129. A fatal case of ceftriaxone (Rocephin)-induced hemolytic anemia associated with intravascular immune hemolysis
130. Ceftazidime-induced hemolysis in a patient with drug-dependent antibodies reactive by immune complex and drug adsorption mechanisms
131. Severe immune-mediated hemolytic anemia secondary to treatment with cefotetan
132. Cephalosporin-induced hemolysis: A case report and review of the literature
133. Ceftizoxime-induced hemolysis due to immune complexes: Case report and determination of the epitope responsible for immune complex-mediated hemolysis
134. Serology of antibodies to second- and third-generation cephalos-porins associated with immune hemolytic anemia and/or positive direct antiglobulin tests
135. Ceftriaxone-induced immune haemolysis: Two case reports and a concise review of the literature
136. Autoimmune haemolytic anaemia associated with alpha-methyldopa therapy
137. Incidence of a positive direct Coombs test in patients on alpha-methyldopa
138. Clinical and serologic management of patients with methyldopa-induced positive antiglobulin tests
139. Autoimmune hemolytic anemia due to levodopa therapy
140. Levodopa induced Coombs positive haemolytic anaemia
141. Dose-related levodopa-induced haemolytic anaemia
142. Reversible haemolytic anaemia after levodopa-carbidopa
143. Procainamide-induced hemolytic anemia in a patient with traumatic cardiac hemolytic anemia
144. Reticulocytopenic, Coombs' positive anemia induced by procainamide
145. Procainamide-induced hemolytic anemia
146. Positive direct antiglobulin tests and immune hemolytic anemia in patients receiving procainamide
147. Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias
148. The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia
149. Cianidanol and its metabolites bind tightly to red cells and are responsible for the production of auto- and/or drug-dependent antibodies against these cells
150. Diclofenac-induced immune haemolytic anaemia: Simultaneous occurrence of red blood cell autoantibodies and drug-dependent antibodies
151. Detection of cell-drug (hapten)-antibody complexes by the gel test
152. Immunohematology
153. Immunologische störungen